Clarivate Epidemiology’s coverage of squamous cell carcinoma of the head and neck comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…
Clarivate Epidemiology’s coverage of squamous cell carcinoma of the head and neck comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…
Clarivate Epidemiology’s coverage of squamous cell carcinoma of the head and neck comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel approaches to reimbursement are rapidly gaining importance. To assist developers of gene…
The rapid growth of digital therapeutic (DTx) solutions to treat medical problems, fueled by increased demand for telehealth services amid the COVID-19 pandemic, has tasked U.S. payers and pharmacy…
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH, substantial…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
The systemic lupus erythematosus (SLE) therapy market in the United States is largely genericized and off-label. With the exception of GlaxoSmithKline’s Benlysta—which launched in 2011—the…
Opioid addiction is a chronic disease, generally driven by a strong and irresistible urge or craving for the intake of opioid drugs and an inability to stop despite negative consequences to health…
Disease stage, primary tumor resectability, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma patients. BRAF/MEK inhibitor combination regimens,…